Therefore, the immune profile captured in an earlier biopsy may not fully represent the tumor contexture, which could lead to misclassification, where a tumor initially low in CD40 expression might evolve to become a high-expressing tumor at a later stage, or vice versa. This evidence concerns the gene CD40 and neoplasm.